Advertisement

Annals of Surgical Oncology

, Volume 18, Issue 2, pp 559–565 | Cite as

Serum Midkine Correlates with Tumor Progression and Imatinib Response in Gastrointestinal Stromal Tumors

  • Tamina Rawnaq
  • Miriam Kunkel
  • Kai Bachmann
  • Ronald Simon
  • Hilke Zander
  • Stephan Brandl
  • Guido Sauter
  • Jakob R. Izbicki
  • Jussuf T. Kaifi
Translational Research and Biomarkers

Abstract

Background

A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients.

Materials and Methods

S-MK concentrations were measured by enzyme-linked immunosorbent assay in GIST patients (n = 96) and healthy controls (n = 148). S-MK levels were then correlated with clinicopathological data and the administration of imatinib therapy. In addition, MK expression was evaluated in 39 surgically resected GIST and in 17 leiomyoma specimens on a tissue microarray.

Results

S-MK concentrations in GIST patients were significantly higher than in healthy controls: median (25th and 75th percentiles) S-MK concentration was 235 (139 and 376) pg/ml in the GIST patients and 99 (33 and 198) pg/ml in the controls (P < 0.001; Mann–Whitney U test). Significantly higher median S-MK concentrations were found in GIST with recurrence compared with those without (295 vs 230; P = 0.009). GIST patients with S-MK levels higher than 400 pg/ml showed a significantly worse recurrence-free survival (P = 0.026; log-rank test). Patients receiving imatinib therapy had decreased median S-MK concentrations compared with those who were not treated with imatinib (331 vs 201; P < 0.001).

Conclusions

S-MK concentration is a potential marker for evaluating the progression and prognosis of GIST, especially during imatinib therapy. Further studies could focus on the role of midkine in the tumorigenesis of GIST and responsiveness toward imatinib therapy.

Keywords

Imatinib Endometrial Carcinoma Oral Squamous Cell Carcinoma Malignant Peripheral Nerve Sheath Tumor Imatinib Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

We thank Sabine Schmidt for her excellent technical assistance. We thank the patients who willingly and generously provided data and samples for research purposes.

Financial Support

This study was funded by research grants from the Dr. Mildred Scheel Stiftung (German Cancer Aid) and supported by a Research Grant from Novartis Oncology, Switzerland.

References

  1. 1.
    Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10:81–9.CrossRefPubMedGoogle Scholar
  2. 2.
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Miettinen M, El-Rifai W, L HLS, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38 Suppl 5:S39–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002;33:459–65.CrossRefPubMedGoogle Scholar
  7. 7.
    Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC. The histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54:96–102.CrossRefPubMedGoogle Scholar
  8. 8.
    Schurr P, Wolter S, Kaifi JT, Reichelt U, Kleinhans H, Wachowiak R, et al. Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome. Clin Cancer Res. 2006;12:5151–57.CrossRefPubMedGoogle Scholar
  9. 9.
    Kadomatsu K. Recent progress of midkine research on cancer. Nippon Rinsho. 2000;58:1337–47.PubMedGoogle Scholar
  10. 10.
    Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277:35990–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer. 2005;114:490–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000;83:701–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 2004;204:127–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Friedrich C, Holtkamp N, Cinatl J, Jr., Sakuma S, Mautner VF, Wellman S, et al. Overexpression of Midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potency. Int J Oncol. 2005;27:1433–40.PubMedGoogle Scholar
  15. 15.
    Fiegel HC, Kaifi JT, Wachowiak R, Quaas A, Aridome K, Ichihara-Tanaka K, et al. Midkine is highly expressed in neuroblastoma tissues. Pediatr Surg Int. 2008;24:1355–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ikematsu S, Nakagawara A, Nakamura Y, Sakuma S, Wakai K, Muramatsu T, et al. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer. 2003;88:1522–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, et al. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett. 1997;233:29–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, et al. Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. Oncol Rep. 2003;10:411–4.PubMedGoogle Scholar
  19. 19.
    Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama A, Takano T, et al. Midkine and its clinical significance in endometrial carcinoma. Cancer Sci. 2008;99:1125–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94:628–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Obata Y, Kikuchi S, Lin Y, Yagyu K, Muramatsu T, Kumai H. Serum midkine concentrations and gastric cancer. Cancer Sci. 2005;96:54–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Kaifi JT, Fiegel HC, Rafnsdottir SL, Aridome K, Schurr PG, Reichelt U, et al. Midkine as a prognostic marker for gastrointestinal stromal tumors. J Cancer Res Clin Oncol. 2007;133:431–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5:1966–75.PubMedGoogle Scholar
  24. 24.
    Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, et al. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer. 2008;99:655–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, Maemura K, et al. Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer. 2007;97:405–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Ren YJ, Zhang QY. Expression of midkine and its clinical significance in esophageal squamous cell carcinoma. World J Gastroenterol. 2006;12:2006–10.PubMedGoogle Scholar
  27. 27.
    Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol. 2006;19:399–406.CrossRefPubMedGoogle Scholar
  28. 28.
    Takahashi R, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, et al. Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology. 2003;64:266–74.CrossRefPubMedGoogle Scholar
  29. 29.
    Takahashi R, Tanaka S, Hiyama T, Ito M, Kitadai Y, Sumii M, et al. Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep. 2003;10:797–802.PubMedGoogle Scholar
  30. 30.
    Huang Y, Cao G, Wang H, Wang Q, Hou Y. The expression and location of midkine in gastric carcinomas of Chinese patients. Cell Mol Immunol. 2007;4:135–40.PubMedGoogle Scholar
  31. 31.
    Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T et al. Midkine as a novel target for antibody therapy in osteosarcoma. Biochem Biophys Res Commun. 2007;358:757–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang Q, Huang Y, Ni Y, Wang H, Hou Y. siRNA targeting midkine inhibits gastric cancer cells growth and induces apoptosis involved caspase-3,8,0 activation and mitochondrial depolarization. J Biomed Sci. 2007;14:783–95.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Tamina Rawnaq
    • 1
  • Miriam Kunkel
    • 1
  • Kai Bachmann
    • 1
  • Ronald Simon
    • 2
  • Hilke Zander
    • 1
  • Stephan Brandl
    • 3
  • Guido Sauter
    • 2
  • Jakob R. Izbicki
    • 1
  • Jussuf T. Kaifi
    • 1
  1. 1.Department of GeneralVisceral and Thoracic Surgery, University Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Institute for PathologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  3. 3.Department of Oncology and HematologyUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations